Editas Medicine, Inc. Total Revenue

• Editas Medicine, Inc. showed an increase of +25.4% in Total Revenue from 2024 to 2025.
• This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $682.0 thousand | Q2 2017: $3.10 million | Q3 2017: $6.28 million | Q1 2018: $3.93 million | Q1 2018: $3.93 million | Q2 2018: $7.37 million | Q2 2018: $7.37 million | Q3 2018: $14.52 million | Q3 2018: $14.52 million | Q4 2018: $6.12 million | Q1 2019: $2.07 million | Q1 2019: $2.07 million | Q2 2019: $2.33 million | Q3 2019: $3.85 million | Q4 2019: $12.28 million | Q1 2020: $5.72 million | Q2 2020: $10.75 million | Q3 2020: $62.84 million | Q4 2020: $11.42 million | Q1 2021: $6.50 million | Q2 2021: $379.0 thousand | Q3 2021: $6.20 million | Q1 2022: $6.77 million | Q2 2022: $6.36 million | Q3 2022: $42.0 thousand | Q1 2023: $9.85 million | Q2 2023: $2.89 million | Q3 2023: $5.34 million | Q1 2024: $1.14 million | Q2 2024: $513.0 thousand | Q3 2024: $61.0 thousand | Q1 2025: $4.66 million | Q2 2025: $3.58 million | Q3 2025: $7.54 million.
• Over the full 12 years of available data (2016 to 2025), Editas Medicine, Inc.'s Total Revenue has grown by 569.4%.
• Historical annual values: Fiscal year 2025: $40.52 million | Fiscal year 2024: $32.31 million | Fiscal year 2023: $78.12 million | Fiscal year 2022: $19.71 million | Fiscal year 2021: $25.54 million | Fiscal year 2020: $90.73 million | Fiscal year 2019: $20.53 million | Fiscal year 2018: $31.94 million | Fiscal year 2018: $31.94 million | Fiscal year 2017: $13.73 million | Fiscal year 2017: $13.73 million | Fiscal year 2016: $6.05 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026